Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/83874/2014
Effective from01/07/2016
KeywordsPharmacokinetics, renal impairment, renal function, renal elimination capacity, kidney, elimination, phase I, glomerular filtration rate (GFR), end-stage renal disease, dialysis, summary of product characteristics, physiologically-based pharmacokinetic modelling (PBPK)
DescriptionThis document gives recommendation on situations when studies of pharmacokinetics should be performed in subjects with decreased renal funtion. It provides guidance on the design of such studies as well as data presentation, analysis, evaluation of results and reflection of those results in the summary of product characteristics.

Document history

First version

Current version

Adopted guideline

Overview of comments

Draft guideline

Concept paper

In operation: 01/07/2016–present

Published: 02/02/2016

Published: 28/02/2014

Published: 08/02/2012

Superseded documentAdopted guidelineIn operation: 01/12/2004–01/07/2016

Related content

How helpful is this page?

Average rating:

 Based on 26 ratings

Add your rating:

See all ratings
5 ratings
5 ratings
5 ratings
5 ratings
6 ratings

Tell us more